Bms-907351
Locally Advanced
Centre Francois BaclessePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 89/ 100
Competitive context
16 Active assets in the Locally Advanced cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Salah Azaïz Cancer Institute | Phase 3 | BB |
(+)-VINCRISTINE Amgen | Phase 3 | BB |
Nivolumab Centre Francois Baclesse | Phase 4 | B |
Epirubicin PMV Pharmaceuticals, Inc | Phase 2 | B |
Conatumumab Amgen | Phase 2 | B |
View all 26 →
Same molecule, other indications
Bms-907351 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →